Management of Nonconvulsive Status Epilepticus in Angelman Syndrome

Up to 50% of patients with Angelman syndrome (AS) will have nonconvulsive status epilepticus (NCSE) with myoclonic or atypical absence status. Adapted from the experience of the Angelman group at Massachusetts General Hospital, this document provides guidance on the outpatient management of patients with AS and NCSE treating with a tapering course of oral diazepam.

While standard clinical EEG can confirm the presence of nonconvulsive status epilepticus (NCSE) in individuals with Angelman syndrome, it is not always necessary.
**NSCE should be suspected with the following constellation of clinical findings:**
- Somnolence
- Fatigue
- Regression
- Increased seizure activity*
- Cluster of seizure activity at onset*
- Decreased activity

Angelman syndrome is a rare genetic disorder and caregivers are often the first to recognize the signs of clinical decline in their child. Their concerns should be heeded and low threshold to consider valium taper if NCSE is confirmed or suspected.

**Recommended Valium Taper Regimen:**
6 day tapering course of oral diazepam (lorazepam can be used if there is a tolerance issue or sensitivity to diazepam)
Beginning with 0.25-0.5 mg/kg/day divided TID x 2 days
Then tapering to BID dosing for 2 days and then daily for 2 days before tapering off entirely

**Example schedule for 20kg child:**
0.3mg/kg/day = 6mg/day

<table>
<thead>
<tr>
<th>DAY</th>
<th>Valium Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-2</td>
<td>2MG TAB TID</td>
</tr>
<tr>
<td>3-4</td>
<td>2MG TAB BID</td>
</tr>
<tr>
<td>5-6</td>
<td>2MG TAB DAILY</td>
</tr>
<tr>
<td>7</td>
<td>OFF VALIUM, BACK TO BASELINE MAINTENANCE MEDICATIONS</td>
</tr>
</tbody>
</table>

In addition, consider increasing maintenance dosing of medications or further carb restriction for children on diet therapy for seizure control to prevent future breakthrough seizures and/or recurrent NCSE.

Some children required repeat tapers or prolonged courses up to 2 weeks to break NCSE.

---


Disclaimer: This document was created and reviewed by the 15q Clinical Research Network clinicians. This should not be considered medical advice, but a resource that you can provide to your medical care teams to help understand seizure activity and treatment options in Angelman Syndrome.